London Daily

Focus on the big picture.
Monday, Oct 12, 2026

Weight loss drug semaglutide approved for NHS use

Weight loss drug semaglutide approved for NHS use

A weight loss jab that has gained popularity in the US has been approved for use by the NHS in England.

The National Institute for Health and Care Excellence (NICE) concluded semaglutide, marketed as Wegovy, is safe, effective and affordable.

Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less.

Famous personalities such as Elon Musk claim to have used it - with a "craze" allegedly developing in Hollywood.


Lifestyle changes


Based on evidence from clinical trials, NICE says semaglutide could help people reduce their weight by over 10%, if implemented alongside nutrition and lifestyle changes.

It will be recommended for use by people with at least one weight-related health condition, as well as those who have a body mass index (BMI) which puts them near the top of the obese range.

BMI is calculated by dividing an adult's weight in kilograms by the square of their height in metres.

Those who are lower on the obese BMI range - a BMI between 30 and 34.9kg/m2 - could also be offered the drug if they have a weight-related health condition. NICE lists these as someone who is pre-diabetic, has type 2 diabetes, high blood pressure, heart disease or obstructive sleep apnoea.

Once-weekly injections of Wegovy will have to be prescribed by a specialist, and an individual will only be able to take the drug for a maximum of two years.

Semaglutide is also found in the diabetes medicine Ozempic, but, unlike Ozempic - which is intended for those with type 2 diabetes - Wegovy is recommended specifically for weight loss.

The drug works as an appetite suppressant by mimicking a hormone called Glucagon-like peptide-1 (GLP-1). This intestinal hormone is released after eating and typically makes people feel fuller, so should help reduce overall calorie intake.

Kailey Wood runs a TikTok account sharing her weight loss journey


An article published last year in Variety suggested the diabetes medicine Ozempic, which contains semaglutide, is being used by some professionals in the film and entertainment industry to lose weight quickly.

It has become so popular that there are currently widespread shortages in the US and concerns for those people who rely on the drug for medical reasons.

Insurance companies in the US are refusing to cover its use among people who are not diabetic and not taking it as a prescribed medicine.


'Ozempic face'


Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor.

Like all medication, semaglutide comes with side-effects and risks - including nausea, stomach pain, vomiting and diarrhoea.

In addition, rapid weight loss can also lead to the skin losing collagen and elastin, causing what Vogue Magazine has dubbed the gaunt "Ozempic face".

Kailey Wood, 36, has been taking Ozempic for seven months, after being prescribed the drug by her doctor in New York.

She tells the BBC that she has lost just under 30kg - going from obese to healthy in the BMI range.

Semaglutide injections will be approved under NICE guidance


"I have Polycystic Ovarian Syndrome (PCOS) and insulin resistance, but honestly I didn't really struggle with my weight until I hit my 30s - after I had my kids," she says.

"I was rapidly gaining weight. I had a personal trainer and was on every diet known to man - keto, low carbohydrate, intermittent fasting and nothing seemed to work,".

When Kailey went for tests with her doctor, she was told she had high blood pressure and high cholesterol and, due to the risks associated with PCOS, she was at risk of developing type 2 diabetes too.

"The long-term effects [of being obese] freaked me out having two daughters," she says.

"I just wanted to get to my best self - to show them what a healthy mum looks like; to get outside and play with them."

Kailey, who works for a tech start-up and runs her own TikTok page, says that people who want to use semaglutide need to know the drug does have side-effects.

"When you start taking this medication, your body almost goes into shock - you get headaches, nausea, tiredness," she explains.

"But your body starts to get used to it. You have to be mindful and listen to your body."

Kailey says those elements of the US media who promoting the drug as a "get skinny quick product" leave "a bad taste". She believes it sends the wrong message.

"What it's really doing is changing people's lives - treating the patient before they have the disease," she says.

Just over a quarter of adults in England are obese and around a third are overweight, according to official figures.

In the UK, obesity is thought to cost the NHS £6.1bn per year, government estimates show.

The drug semaglutide is currently under consultation in Scotland, with Wales expected to follow the NICE guidelines issued in England.

Helen Knight, director of medicines evaluation at NICE, said: "For some people losing weight is a real challenge, which is why a medicine like semaglutide is a welcome option.

"It won't be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer."

Dr Duane Mellor, registered dietitian and senior lecturer at Aston Medical School, Aston University, said: "It is important to remember that living with a higher body weight or obesity is not a lifestyle choice, and people wanting to improve their health should be supported to do that.

"It is also clear that semaglutide is not intended to be a lifestyle weight-loss product in the UK. It is to be used for the purpose of improving health."

Anyone who is offered semaglutide on the NHS will be supported by specialist weight management services, including support from a dietitian.

Newsletter

Related Articles

0:00
0:00
Close
UK Prime Minister Andy Burnham Meets German Chancellor Merz to Strengthen European Security Ties
Nearly 100,000 NHS Patients Treated in Hospital Corridors as England Braces for Winter Pressures
UK Government Rejects US-Russia Diesel Agreement and Reaffirms Sanctions Against Moscow
UK and Germany Agree to Deepen Security and Economic Cooperation Following Berlin Talks
British Prime Minister Burnham Pledges Closer EU Ties During Visit to Germany
UK Announces New Sanctions on 17 Russia-Linked Entities During Foreign Secretary's Ukraine Visit
UK and Germany Finalize Kensington Treaty to Strengthen Defense and Technology Cooperation
Britain Maintains Diplomatic Mission in East Jerusalem Despite Israeli Closure Deadline
English Councils Push Government to Rethink Proposed Funding Cuts
Scottish Homebuilding Falls to Lowest Level in 11 Years
BBC Chief Matt Brittin Defends Restructuring as Staff Challenge Job Cuts
UK Finance Warns High Energy Costs and Bond Yields Are Complicating Fiscal Outlook
UK Adopts All 44 Recommendations on Regulating AI in Healthcare
Chancellor John Healey Prepares Autumn Budget as Borrowing Costs Strain Public Finances
UK Investigators See Strong Indications of Iranian Link After RAF Fairford Security Operation
Laura Trott Pledges Tighter Controls on Political Activism in UK Classrooms
Welsh Ministers Launch Long-Term Review of North Wales and Anglesey Crossings
Welsh Government Orders 18-Month Study of Road Solutions Around Newport
Reform UK MP Sarah Pochin Faces Scrutiny Over £800,000 Second Home Purchase
British Households Grow More Concerned About Fuel and Energy Prices
NHS Leaders Warn of Rising Winter Pressure on Emergency Departments
Kemi Badenoch Proposes £2.3 Billion Employer National Insurance Cut for Young Workers
Middle East Conflict Could Erase UK Fiscal Headroom, Economists Warn
Manchester City Found Guilty of Multiple Premier League Financial Rule Breaches
UK Security Services Find Strong Indications of Iranian Role in RAF Fairford Incident
Costa Coffee Returns to Operating Profit on Iced Drinks and Menu Changes
Asos Warns Customers After Unauthorized Access to Retail App and Data
Kemi Badenoch Puts Growth and Deregulation at Center of Conservative Conference
Campaigners Warn of Deepening Social Care Crisis for Disabled Adults
Study Finds Rising Early-Onset Cancer Rates Among Adults Under 50 in Britain
UK Coach Operators Warn High Diesel Prices Could Force Route Cuts
FCA Opens Independent Review Into Handling of Epstein-Linked Whistleblower Case
Argentina Vows to Block Falkland Islands Offshore Oil Development
UK Chancellor Prepares Fiscal Measures and Welfare Reforms Ahead of Autumn Budget
Sainsbury’s and Morrisons Explore Potential Multi-Billion-Pound Merger
UK Weighs Tariffs on Chinese Electric Vehicles to Align With European Union
UK Threatens Diplomatic Expulsions Over Planned Closure of East Jerusalem Consulate
UK Energy Price Cap Hits Three-Year High as Middle East Conflict Raises Costs
Seventh Arrest Made in Suspected Terror Plot at RAF Fairford
Systemic Education Collapse Sparks Mass Student Uprisings in France
Green Party Faces Backlash Over Resolution Equating Zionism With Racism
Conservatives Debate Scrapping Environmental Rules for New Homes
Cornwall Insight Warns UK Energy Bills Could Approach £2,000 This Winter
UK Coach Operators Warn of Service Cuts as Diesel Prices Exceed £2
Scottish Parliament Approves £68 Billion Budget With New Tax and Property Measures
FCA Opens Independent Review Into Handling of Epstein Whistleblower
UK Government Drops Plan to Suspend Jury Trials in England and Wales
Bank of England Holds Interest Rate at 3.75% as Markets Watch November
Two Iranian Nationals Charged Over Alleged Plot Targeting Manchester Jewish Community
UK Fiscal Headroom Halves to £11 Billion Ahead of Budget, EY Warns
×